James B. Bussel, MD:An important issue is, how would we know that she has ITP? We’ve alluded to the idea that she has no findings consistent with another diagnosis. We don’t know exactly how high her platelets went with the steroids in this case. If they had gone up substantially, that would argue in favor of ITP because she would have responded to treatment. This would be particularly true if she had received, for example, IV gamma globulin and if the platelets had gone up very rapidly, for example, within 2, 3, 4, or 5 days. If the platelet increase took weeks, it would be distinctly unlikely but not impossible that this was a case of leukemia. If there were any reasons to consider leukemiaperhaps the way the smear looked or slight leucopenia or something else—it might be important to do a bone marrow aspirate and/or biopsy to make sure that this is not the case. The fact that she is followed up, gets 2 courses of prednisone—which she tapers off and discontinues and does not have any progression—does not develop hepatosplenomegaly or lymphadenopathy, does not develop anemia or abnormal white count, etc, argues strongly that this is ITP and not leukemia or some other diagnosis.
However, that still does not mean that everything will automatically be OK. We know that she may persist and have chronic ITP. It could be more severe as opposed to less severe. She could develop another medical problem, have trauma, or something like that that would make her at higher risk with a low platelet count. She could develop other autoimmune diseases, especially thyroid disease but also lupus erythematosus. She also could have her life complicated by development of fatigue associated with thrombocytopenia, or she could have it complicated by becoming iron deficient if her menses get heavy, or since she takes occasional ibuprofen, we don’t know whether that’s for headaches or for joint pains. But since she can no longer take that, other treatments like that may be less effective, and therefore, her quality of life may decrease somewhat as a result.
Transcript edited for clarity.
Case: A 48-year-old woman presenting with unusual bruising
October 2017
April 2018
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
Brunner Discusses Dosing Approaches for ESA and Novel Therapies for Low-Risk MDS
December 23rd 2024During a Case-Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.
Read More
Epcoritamab Delivers Durable Responses in Anthracycline-Ineligible LBCL
December 12th 2024Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.
Read More